Estados Unidos · Agencias y tiempo real · PR Newswire

Therakos Receives MDR Approval in Europe for Treating Immune-Related Adverse Events in Patients with Inadequate Response to Corticosteroids

Publicado por PR Newswire · Estados Unidos hace 1 h

DUBLIN, Oct. 21, 2026 /PRNewswire/ -- Therakos Development Limited, a global pioneer in immunomodulatory therapy delivered at the bedside through extracorporeal photopheresis…

Leer el artículo completo en PR Newswire Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.prnewswire.com)

Therakos Receives MDR Approval in Europe for Treating Immune-Related Adverse Events in Patients with Inadequate Response to Corticosteroids

También te puede interesar

Here’s why Rubio is visiting a small Indian city home to world’s largest oil-refining complex

Accenture, Dragos and SANS Institute Launch Foundation to Strengthen Cyber Defenses for Under-Resourced U.S. Utilities

Episode 49: Trump’s Tariffs Give Forced-Labor Activists an Opening

MT Newswires' MCP Server Now Available in Perplexity Computer, Bringing Real-Time Global Market News to AI-Driven Workflows

Therakos Receives MDR Approval in Europe for Treating Immune-Related Adverse Events in Patients with Inadequate Response to Corticosteroids

Compartir

También te puede interesar

Here’s why Rubio is visiting a small Indian city home to world’s largest oil-refining complex

Accenture, Dragos and SANS Institute Launch Foundation to Strengthen Cyber Defenses for Under-Resourced U.S. Utilities

Episode 49: Trump’s Tariffs Give Forced-Labor Activists an Opening

MT Newswires' MCP Server Now Available in Perplexity Computer, Bringing Real-Time Global Market News to AI-Driven Workflows